Current Consensus on I-131 MIBG Therapy
Sign Up to like & getrecommendations! Published in 2018 at "Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s13139-018-0523-z
Abstract: Metaiodobenzylguanidine (MIBG) is structurally similar to the neurotransmitter norepinephrine and specifically targets neuroendocrine cells including some neuroendocrine tumors. Iodine-131 (I-131)-labeled MIBG (I-131 MIBG) therapy for neuroendocrine tumors has been performed for more than a quarter-century.… read more here.
Keywords: unresectable metastatic; 131 mibg; mibg therapy; mibg ... See more keywords
Single‐institution experience of radioembolization with yttrium‐90 microspheres for unresectable metastatic neuroendocrine liver tumors
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.13752
Abstract: The aim of this study was to assess the effectiveness of yttrium‐90 (90Y) microspheres for the treatment of unresectable metastatic liver neuroendocrine tumors (NET). read more here.
Keywords: unresectable metastatic; experience radioembolization; yttrium; liver ... See more keywords
Novel therapies for unresectable and metastatic melanoma
Sign Up to like & getrecommendations! Published in 2017 at "British Medical Journal"
DOI: 10.1136/bmj.j5174
Abstract: #### What you need to know A 60 year old white woman who had a melanoma excised a year ago now presents with multiple subcutaneous nodules along her left shin. Biopsy confirms the lesions as… read more here.
Keywords: melanoma; unresectable metastatic; year; metastatic melanoma ... See more keywords
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-16-2422
Abstract: On January 28, 2016, the FDA approved eribulin (Halaven; Eisai Inc.) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. The approval was based on results from… read more here.
Keywords: received prior; unresectable metastatic; liposarcoma; patients unresectable ... See more keywords
Abstract 4279: GermlineBRCAmutations in Asian patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma (PDAC): Risk categories for genetic testing in Asian population
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-4279
Abstract: Background: Familial PDAC constitutes of 5-10% of all PDAC, and germline mutations in BRCA1 and BRCA2 are associated with increased risk of PDAC. Although previous studies showed the prevalence of BRCA1 and BRCA2 germline mutations… read more here.
Keywords: unresectable metastatic; germline; pdac; advanced unresectable ... See more keywords
Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2020 at "World Journal of Surgical Oncology"
DOI: 10.1186/s12957-020-01972-y
Abstract: Background The impact of primary tumor resection (PTR) on the prognosis of unresectable metastatic colorectal cancer (mCRC) patients remains debatable. We aimed to develop several prognostic nomograms which could be useful in predicting whether patients… read more here.
Keywords: metastatic colorectal; unresectable metastatic; tumor resection; metastasis ... See more keywords
Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients : A retrospective cohort study.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.9540
Abstract: 9540Background: Vemurafenib is used for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. The approved fixed vemurafenib dose of 960 mg twice dai... read more here.
Keywords: v600 mutation; positive unresectable; unresectable metastatic; mutation positive ... See more keywords
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9507
Abstract: 9507 Background: First-line treatment with D+T demonstrated prolonged progression-free survival (PFS) and overall survival (OS) in patients with BRAF V600–mutant unresectable or metastatic melanoma. With 5 years of follow-up, we report survival and describe characteristics… read more here.
Keywords: mutant unresectable; metastatic melanoma; unresectable metastatic; year ... See more keywords
Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9510
Abstract: 9510 Background: There are no validated blood-based biomarkers to monitor efficacy in pts with advanced melanoma. Lactate dehydrogenase (LDH) is an established prognostic factor; however, it is not normally used to inform treatment decisions. ctDNA… read more here.
Keywords: ctdna; metastatic melanoma; melanoma treated; unresectable metastatic ... See more keywords
A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell carcinoma (CSCC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e21020
Abstract: e21020 Background: Patients (pts) with unresectable/metastatic CSCC have a poor prognosis, and until recently had limited treatment options. Based on encouraging efficacy in case report series, we conducted a phase 2 trial to evaluate the… read more here.
Keywords: cscc; study; peg ifna; unresectable metastatic ... See more keywords
Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.8_suppl.18
Abstract: 18 Background: Due to their immuno-modulatory effects, anti-angiogenic drugs have been clinically investigated in combination with anti-PD-1 therapies. The addition of rivoceranib (apatinib), a highly-selective VEGFR-2 tyrosine kinase inhibitor, is being evaluated in an ongoing… read more here.
Keywords: part; rivoceranib apatinib; efficacy; study ... See more keywords